ID

19354

Beschreibung

Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment; ODM derived from: https://clinicaltrials.gov/show/NCT00337350

Link

https://clinicaltrials.gov/show/NCT00337350

Stichworte

Versionen (1)
  1. 20.12.16 20.12.16 -
Hochgeladen am

20. Dezember 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Schizophrenia NCT00337350

Englisch

Eligibility Schizophrenia NCT00337350

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female
Beschreibung

Gender

Datentyp

boolean

Alias
UMLS CUI [1]
C0079399
age 18-65 years
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
diagnosis of schizophrenia, any subtype, schizoaffective disorder, any subtype or schizophreniform disorder
Beschreibung

Schizophrenia Subtype Any | Schizoaffective Disorder Subtype Any | Schizophreniform Disorder

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0036341
UMLS CUI [1,2]
C0449560
UMLS CUI [1,3]
C1552551
UMLS CUI [2,1]
C0036337
UMLS CUI [2,2]
C0449560
UMLS CUI [2,3]
C1552551
UMLS CUI [3]
C0036358
well established compliance with out-patient medications
Beschreibung

Outpatients Pharmaceutical Preparations Compliance

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0029921
UMLS CUI [1,2]
C0013227
UMLS CUI [1,3]
C3714738
current treatment with clozapine for a minimum of one year
Beschreibung

Clozapine

Datentyp

boolean

Alias
UMLS CUI [1]
C0009079
evidence of insulin resistance: impaired fasting glucose (glucose ≥100 mg/dl) or hyperinsulinemia (fasting insulin ≥ 15 ng/dl) or a homa-ir (homeostasis model assessment for insulin resistance) (fasting glucose x fasting insulin/22.5) ≥2 or a si (insulin sensitivity index)
Beschreibung

Insulin Resistance Evidence of | Impaired fasting glucose | Glucose measurement | Hyperinsulinism | fasting insulin level | Homeostasis model assessment Insulin Resistance | Insulin Sensitivity Index

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0021655
UMLS CUI [1,2]
C0332120
UMLS CUI [2]
C1272092
UMLS CUI [3]
C0337438
UMLS CUI [4]
C0020459
UMLS CUI [5]
C2016107
UMLS CUI [6,1]
C1829779
UMLS CUI [6,2]
C0021655
UMLS CUI [7,1]
C0920563
UMLS CUI [7,2]
C0918012
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
inability to provide informed consent
Beschreibung

Informed Consent Unable

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
current substance abuse
Beschreibung

Substance Use Disorders

Datentyp

boolean

Alias
UMLS CUI [1]
C0038586
significant medical illness, including congestive heart failure, severe cardiovascular disease, renal disease (serum creatinine > 1.5), anemia (hemoglobin < 11.0 gm/dl) or psychiatrically unstable
Beschreibung

Illness Significant | Congestive heart failure | Cardiovascular Disease Severe | Kidney Diseases | Creatinine measurement, serum | Anemia | Hemoglobin measurement | Psychiatric Unstable

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0750502
UMLS CUI [2]
C0018802
UMLS CUI [3,1]
C0007222
UMLS CUI [3,2]
C0205082
UMLS CUI [4]
C0022658
UMLS CUI [5]
C0201976
UMLS CUI [6]
C0002871
UMLS CUI [7]
C0518015
UMLS CUI [8,1]
C0205487
UMLS CUI [8,2]
C0443343
severe hepatic impairment, active liver disease or increased serum transaminase levels (alt>2.0x upper limit of normal) if at any time, alt increases to 2x uln, the subject's participation in the study will be terminated.
Beschreibung

Hepatic impairment Severe | Liver diseases | Serum transaminase increased | Alanine aminotransferase measurement | Study Subject Participation Status

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0948807
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C0023895
UMLS CUI [3]
C0859350
UMLS CUI [4]
C0201836
UMLS CUI [5]
C2348568
women of child bearing potential who are pregnant, breastfeeding, or who are unwilling or unable to use an effective form of birth control during the entire study
Beschreibung

Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods Unable | Childbearing Potential Contraceptive methods Unwilling

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C1299582
UMLS CUI [4,1]
C3831118
UMLS CUI [4,2]
C0700589
UMLS CUI [4,3]
C0558080
treatment with agents that induce weight loss
Beschreibung

Weight-Loss Agents

Datentyp

boolean

Alias
UMLS CUI [1]
C0376606
history of diabetes mellitus or thyroid disease
Beschreibung

Diabetes Mellitus | Thyroid Diseases

Datentyp

boolean

Alias
UMLS CUI [1]
C0011849
UMLS CUI [2]
C0040128
current treatment with an oral hypoglycemic agent or insulin
Beschreibung

Oral hypoglycemic | Insulin

Datentyp

boolean

Alias
UMLS CUI [1]
C0359086
UMLS CUI [2]
C0021641
known hypersensitivity to rosiglitazone or any of its components
Beschreibung

Hypersensitivity rosiglitazone | Hypersensitivity rosiglitazone Component

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0289313
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0289313
UMLS CUI [2,3]
C1705248
fasting glucose >126 mg/dl11. treatment with other atypical antipsychotic agents thought to impair glucose metabolism (olanzapine) or low potency conventional agents (thioridazine, chlorpromazine)
Beschreibung

Glucose measurement, fasting | Atypical antipsychotic Impairing Glucose metabolism | olanzapine | Pharmaceutical Preparations conventional Potency low | Thioridazine | Chlorpromazine

Datentyp

boolean

Alias
UMLS CUI [1]
C0202045
UMLS CUI [2,1]
C1276996
UMLS CUI [2,2]
C0221099
UMLS CUI [2,3]
C0596620
UMLS CUI [3]
C0171023
UMLS CUI [4,1]
C0013227
UMLS CUI [4,2]
C0439858
UMLS CUI [4,3]
C0678792
UMLS CUI [4,4]
C0205251
UMLS CUI [5]
C0039943
UMLS CUI [6]
C0008286
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Schizophrenia NCT00337350

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Gender
Item
male or female
boolean
C0079399 (UMLS CUI [1])
Age
Item
age 18-65 years
boolean
C0001779 (UMLS CUI [1])
Schizophrenia Subtype Any | Schizoaffective Disorder Subtype Any | Schizophreniform Disorder
Item
diagnosis of schizophrenia, any subtype, schizoaffective disorder, any subtype or schizophreniform disorder
boolean
C0036341 (UMLS CUI [1,1])
C0449560 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
C0036337 (UMLS CUI [2,1])
C0449560 (UMLS CUI [2,2])
C1552551 (UMLS CUI [2,3])
C0036358 (UMLS CUI [3])
Outpatients Pharmaceutical Preparations Compliance
Item
well established compliance with out-patient medications
boolean
C0029921 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C3714738 (UMLS CUI [1,3])
Clozapine
Item
current treatment with clozapine for a minimum of one year
boolean
C0009079 (UMLS CUI [1])
Insulin Resistance Evidence of | Impaired fasting glucose | Glucose measurement | Hyperinsulinism | fasting insulin level | Homeostasis model assessment Insulin Resistance | Insulin Sensitivity Index
Item
evidence of insulin resistance: impaired fasting glucose (glucose ≥100 mg/dl) or hyperinsulinemia (fasting insulin ≥ 15 ng/dl) or a homa-ir (homeostasis model assessment for insulin resistance) (fasting glucose x fasting insulin/22.5) ≥2 or a si (insulin sensitivity index)
boolean
C0021655 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C1272092 (UMLS CUI [2])
C0337438 (UMLS CUI [3])
C0020459 (UMLS CUI [4])
C2016107 (UMLS CUI [5])
C1829779 (UMLS CUI [6,1])
C0021655 (UMLS CUI [6,2])
C0920563 (UMLS CUI [7,1])
C0918012 (UMLS CUI [7,2])
Item Group
C0680251 (UMLS CUI)
Informed Consent Unable
Item
inability to provide informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Substance Use Disorders
Item
current substance abuse
boolean
C0038586 (UMLS CUI [1])
Illness Significant | Congestive heart failure | Cardiovascular Disease Severe | Kidney Diseases | Creatinine measurement, serum | Anemia | Hemoglobin measurement | Psychiatric Unstable
Item
significant medical illness, including congestive heart failure, severe cardiovascular disease, renal disease (serum creatinine > 1.5), anemia (hemoglobin < 11.0 gm/dl) or psychiatrically unstable
boolean
C0221423 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0018802 (UMLS CUI [2])
C0007222 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0022658 (UMLS CUI [4])
C0201976 (UMLS CUI [5])
C0002871 (UMLS CUI [6])
C0518015 (UMLS CUI [7])
C0205487 (UMLS CUI [8,1])
C0443343 (UMLS CUI [8,2])
Hepatic impairment Severe | Liver diseases | Serum transaminase increased | Alanine aminotransferase measurement | Study Subject Participation Status
Item
severe hepatic impairment, active liver disease or increased serum transaminase levels (alt>2.0x upper limit of normal) if at any time, alt increases to 2x uln, the subject's participation in the study will be terminated.
boolean
C0948807 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0023895 (UMLS CUI [2])
C0859350 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C2348568 (UMLS CUI [5])
Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods Unable | Childbearing Potential Contraceptive methods Unwilling
Item
women of child bearing potential who are pregnant, breastfeeding, or who are unwilling or unable to use an effective form of birth control during the entire study
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C1299582 (UMLS CUI [3,3])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0558080 (UMLS CUI [4,3])
Weight-Loss Agents
Item
treatment with agents that induce weight loss
boolean
C0376606 (UMLS CUI [1])
Diabetes Mellitus | Thyroid Diseases
Item
history of diabetes mellitus or thyroid disease
boolean
C0011849 (UMLS CUI [1])
C0040128 (UMLS CUI [2])
Oral hypoglycemic | Insulin
Item
current treatment with an oral hypoglycemic agent or insulin
boolean
C0359086 (UMLS CUI [1])
C0021641 (UMLS CUI [2])
Hypersensitivity rosiglitazone | Hypersensitivity rosiglitazone Component
Item
known hypersensitivity to rosiglitazone or any of its components
boolean
C0020517 (UMLS CUI [1,1])
C0289313 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0289313 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
Glucose measurement, fasting | Atypical antipsychotic Impairing Glucose metabolism | olanzapine | Pharmaceutical Preparations conventional Potency low | Thioridazine | Chlorpromazine
Item
fasting glucose >126 mg/dl11. treatment with other atypical antipsychotic agents thought to impair glucose metabolism (olanzapine) or low potency conventional agents (thioridazine, chlorpromazine)
boolean
C0202045 (UMLS CUI [1])
C1276996 (UMLS CUI [2,1])
C0221099 (UMLS CUI [2,2])
C0596620 (UMLS CUI [2,3])
C0171023 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0439858 (UMLS CUI [4,2])
C0678792 (UMLS CUI [4,3])
C0205251 (UMLS CUI [4,4])
C0039943 (UMLS CUI [5])
C0008286 (UMLS CUI [6])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video